November 2, 2015 / 6:18 PM / 3 years ago

BUZZ-Improved prognosis for U.S. healthcare stocks

** Healthcare is day’s leading S&P sector, adding to recent gains, with the index up 1.9 pct

** Nasdaq Biotechnology index up 3.2 pct

** Today’s move by the SPXHC follows last week’s 3-pct gain, its best week since March, after a string of solid earnings reports from blue chips

** Shares of AbbVie today’s top index winners, and up 17 pct over last two days, on back of strong results and bullish outlook for its arthritis drug, Humira

** Goldman Sachs adds AbbVie to its conviction Buy list and ups PT to $80, implying more than 33 pct upside from current levels

** Cardinal Health day’s next best performer, up 4.5 pct, after drug distribution co’s beat and raise

** Pfizer and Celgene both climb 3.6 pct

** Specialty pharma co’s Mallinckrodt PLC and Endo International higher in relief rally as short-seller Citron dials back from its Friday tweet about Valeant

** SPXHC and NBI now 14 pct and 18 pct off their respective late Sept lows as investors hunt for bargains after the steep 3-month biotech selloff (RM:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below